There are options to help prevent RSV and its potential serious consequences on infants and older adults this respiratory season. ABRYSVOTM (Respiratory Syncytial Virus Vaccine) from Pfizer is the only FDA-approved and ACIP-recommended RSV vaccine to help protect both older adults and infants (via maternal immunization) from RSV.

RSV can lead to serious outcomes in older adults (annual data)

2.2 million symptomatic illnesses
60,000-160,000 hospitalizations
6000-10,000 deaths

RSV is the leading cause of hospitalization in infants aged <1 year

Hospitalization burden is greatest in infants under 6 months of age, peaking between 1 and 2 months of age 3
In severe cases, RSV may result in acute respiratory failure, hypoxia and carbon dioxide retention, apnea, and death

Please review the Indications and Important Safety Information for ABRYSVO™ below.

ABRYSVO™ is ACIP recommended

The CDC’s ACIP recommends ABRYSVO™ for adults 60 years and older based on shared clinical decision making.6 The recommendation was published in the July 21, 2023, issue of MMWR, and is available here.
The CDC's ACIP recommends ABRYSVO for pregnant people as a one-time dose at 32 weeks and zero days’ through 36 weeks and 6 days’ gestation using seasonal administration (meaning September–January in most of the continental United States) for prevention of RSV-associated LRTI in infants aged <6 months. The recommendation was published in the October 6, 2023, issue of MMWR, and is available here.

ABRYSVO™ is ACOG recommended

The American College of Obstetricians and Gynecologists (ACOG) recommends a single dose of maternal RSV vaccination for pregnant individuals 32 through 36 weeks gestation*, using seasonal administration, to prevent RSV lower respiratory tract infection in infants.

* Beginning on the first day of the 32nd week through the last day of the 36th week